Role of SIRT1 in Regulation of Epithelial-to-mesenchymal Transition in Breast Cancer Lymph Nodes Metastasis

NCT04137406 | Unknown

• 1 other identifier: Luminal A sirt1
• Study Type: observational
• Target: 160
• Locations: 1 country
• Sites: 1

Brief Summary

Luminal A breast cancer is a kind of breast cancer with low rate lymph node metastasis and good survival. But in clinical practice, Luminal A breast cancer can present with early, unexpected lymph node metastasis some time, indicates poor survival. Silent information regulator 2 homolog 1 (SIRT1) plays a different role in breast cancer with different molecular typing. Previous study supports a role of SIRT1 protein as tumor suppressor in Luminal A breast cancer, in association with apoptosis-related proteins. The epithelial-to-mesenchymal transition(EMT) process results in loss of cell-cell adhesion, increased cell mobility, and is crucial for enabling the metastasis of cancer cells. But no similar study in Luminal A breast cancer. Hence, this study will 1) investigate the expression pattern of SIRT1 in primary tumor and lymph node metastasis; 2) investigate the different expression pattern of SIRT1 in T2/T3 , lymph node negative tumor and T1, lymph node positive tumor; 3) investigate potential role of SIRT1 enzyme in regulating cell migration and invasion in Luminal A breast cancer cells.

Conditions

Breast Cancer; Lymph Node Metastases

Keywords

Luminal A breast cancer; Sirt 1; lymph node metastasis; EMT

Outcome Measures

Primary Outcomes (1)

• Protein expression difference

  the different of sirt1 expression between T1N+ tumor and T2N0/T3M0 tumor

  2020-2

Secondary Outcomes (1)

• survival

  2021-2

Study Arms (2)

T1 tumor with lymph node metastasis

patients with T1 tumor and lymphnode positive

T2 or T3 tumor with lymph node negative

patients with T2 or T3,lymph node negative

Eligibility Criteria

• Sex: female
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

all the patients have invasive breast cancer with luminal A subtype group 1: T1 and lymph node positve group 2: T2/T3 with negative lymph node

You may qualify if:

• Invasive breast cancer Luminal A subtype T1 and lymph node positive or T2/T3 with negative lymph node

You may not qualify if:

• Missing clinical pathology data

Sponsors & Collaborators

• Peking University People's Hospital: lead

Study Sites (1)

Peking university people's hospital

Beijing, Beijing Municipality, 100044, China

RECRUITING

Biospecimen

Retention: SAMPLES WITHOUT DNA

Paraffin section, immunohistochemical staining

MeSH Terms

Conditions

Breast Neoplasms; Lymphatic Metastasis

Condition Hierarchy (Ancestors)

Neoplasms by Site; Neoplasms; Breast Diseases; Skin Diseases; Skin and Connective Tissue Diseases; Neoplasm Metastasis; Neoplastic Processes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• shu wang, Doctor

  Peking University People's Hospital

  STUDY DIRECTOR

Central Study Contacts

yuan peng, Doctor

CONTACT

+8613671287670; 13671287670@163.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 22, 2019
• First Posted: October 24, 2019
• Study Start: January 1, 2019
• Primary Completion: December 30, 2020
• Study Completion: December 30, 2020
• Last Updated: October 24, 2019

Record last verified: 2019-10

Locations

CN (1)